Sign in Subscribe
Pharmaceutical industry

AVAX Technologies Initiates Pivotal Trial for M-Vax Vaccine Treatment

Strategic Insights

— 2 min read

AVAX Technologies, a biopharmaceutical company, has initiated a pivotal trial for M-Vax, an experimental autologous vaccine designed to treat Stage 3 melanoma. The study aims to enroll 400 patients and compare the efficacy of M-Vax against high dose alpha interferon. The trial's primary endpoints are the rate of melanoma tumor recurrence and overall survival. Previous studies have shown that M-Vax can produce a positive immune response in over two-thirds of patients, with a nearly 60% five-year survival rate among melanoma patients treated with the vaccine.

Key Takeaways:

  • The pivotal trial for M-Vax will enroll approximately 400 patients and compare the efficacy of the vaccine against high dose alpha interferon.
  • The trial's primary endpoints are the rate of melanoma tumor recurrence and overall survival.
  • Previous studies have shown that M-Vax can produce a positive immune response in over two-thirds of patients, with a nearly 60% five-year survival rate among melanoma patients treated with the vaccine.
  • The vaccine works by "training" the patient's immune system to attack cancer cells via a natural process, with low toxicity.
  • AVAX Technologies has also developed O-VAX, an ovarian cancer vaccine, which has shown positive results in a recent study with 6 out of 7 patients having a positive reaction to their own ovarian cancer cells.
  • AVAX's development team has successfully navigated the regulatory requirements for M-Vax, allowing the company to rapidly move forward with the clinical trial.
  • The study will utilize the same dosing regimen as a previous Phase II study, which demonstrated the vaccine's ability to produce a positive DTH response in two-thirds of patients.

Statistics:

  • 500,000 people worldwide suffer from melanoma.
  • 400 patients will be enrolled in the pivotal trial for M-Vax.
  • Over two-thirds of patients who received M-Vax in a previous Phase II study developed an immune response against their own tumor cells.
  • The vaccine produced a nearly 60% five-year survival rate among melanoma patients treated with M-Vax.
  • 6 out of 7 ovarian cancer patients treated with O-VAX had a positive reaction to their own ovarian cancer cells.
  • The dose-response rate for M-Vax was 60% in the Phase II study.

Sources:

  • "AVAX Technologies, Inc. Interview with Jeffrey M. Jonas, MD," Prnewswire.com, July 27, 1998.
  • "Annual Report on Form 10-KSB for the fiscal year ended December 31, 1997," Securities and Exchange Commission.
  • "Quarterly Report on Form 10-QSB for the Period Ended March 31, 1998," Securities and Exchange Commission.

Read more